A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

Inclusion Criteria:

• Eligible participants aged ≥18 years.

• Have relapsed/refractory mature B-cell non-Hodgkin lymphoma (NHL) and ≥2 priorsystemic therapies, or histologically confirmed AITL that has recurred or progressedfollowing institutional standard-of-care therapy.

• Participants must also have ≥1 measurable lesion at study entry

• Eastern Cooperative Oncology Group performance status of 0 or 1,

• Freshly biopsied or archival tumor tissue available,

• Participants with adequate organ function,

• Participants must accept and follow pregnancy prevention guidance.

Exclusion Criteria:

• No prior allogeneic stem cell transplant or solid organ transplantation, Autologousstem cell transplant, must not have occurred ≤100 days, previous CAR T-cell therapy ≤60 days, radiotherapy ≤ 2 weeks, systemic anticancer treatment ≤ 5 half-lives or 4weeks, prior to ARV-393 treatment initiation.

• Participants must not have significant acute or chronic medical illness, includinghypereosinophilic syndrome, active interstitial lung disease or pneumonitis, activeor uncontrolled infection, or the presence of laboratory abnormalities, that placesparticipants at unacceptable risk if participating in this study.

• Participants with an inability to comply with listed prohibited treatments.